Because EGFR inhibitors are used in clinics for the treatment of several cancers (8, 9), in this work, we characterized the role of EGFR on cardiomyocyte cohesion and the efficacy of erlotinib to modulate adhesion. This evidence concerns the gene EGFR and cancer.